Key TakeawaysThe S&P 500 fell 1.1% on Tuesday, Jan. 7, as U.S. manufacturing data reinvigorated concerns about inflation and the interest rate outlook.Shares of data analytics software firm Palantir lost ground for the second straight session after Morgan Stanley analysts cited valuation concerns.Moderna shares surged as reports of the country's first bird-flu fatality sparked interest in the biotech firm's experimental H5N1 vaccine. Major U.S. equities indexes lost ground as the latest Purchasing Managers' ...

Key TakeawaysModerna shares jumped more than 10% to lead S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S.The biotech company is developing a vaccine for H5N1.Despite Tuesday's gains, Moderna shares are down more than 55% over the past year. Moderna (MRNA) shares jumped more than 10% to lead S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S. The biotech company is developing a vaccine for H5N1. On Monday, the Centers for Disease Contro ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

In the latest trading session, Moderna (MRNA) closed at $42.18, marking a +0.43% move from the previous day. This change lagged the S&P 500's 1.26% gain on the day. Elsewhere, the Dow saw an upswing of 0.8%, while the tech-heavy Nasdaq appreciated by 1.77%.The the stock of biotechnology company has fallen by 2.19% in the past month, leading the Medical sector's loss of 6.56% and the S&P 500's loss of 2.82%.Market participants will be closely following the financial results of Moderna in its upcoming release ...

Originally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising my background in life sciences to assess the potential of novel treatments, including those using CGT, as well as, their capacity to drive shareholders' returns. Thus, as SA analyst, I will be focusing on analysing biotechnology, pharmac ...

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna (MRNA) have been sliding down over the past few years due to waning demand for the vaccine.In the past three months, MRNA stock has lost nearly 40%, significantly underperforming the industry’s 17.1% decline, as seen in the chart below. While the company’s pipeline progress has been encouraging, the update to its business outlook for the next four years and a curtailed R&D budget did not sit well ...

Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "mRNA Vaccines and Therapeutics Market by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-user, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering.The global mRNA vaccines and therapeutics market size reached US$ 57.7 billion in 2023. Looking forward, the market is expected to reach US$ 72.7 billion by 2032, exhibiting a growth rate (CAGR) of 2.6% during 2023-2032. The development and acceptance of mRNA-based ...

公司信息 * **公司名称**：Moderna, Inc. (NASDAQ:MRNA) * **公司业务**：mRNA疫苗和药物的开发 * **公司地位**：mRNA疫苗和药物领域的领先开发者 * **公司财务状况**：拥有强劲的资产负债表 核心观点和论据 * **RFK Junior提名事件**：公司CEO Stephane Bancel表示，公司将继续与医生、护士和消费者合作，传播事实和数据，以应对关于疫苗的误信息和政治噪音。[序号6] * **COVID疫苗**：Moderna正在开发下一代COVID疫苗mRNA-1283，该疫苗具有更高的效力和针对65岁以上人群的定位。公司计划在2024年底前提交上市申请。[序号10][序号19] * **流感疫苗**：Moderna正在开发流感COVID组合疫苗mRNA-1083，该疫苗具有针对COVID的高剂量性能，并显示出与Fluzone HD的非劣效性。[序号12][序号19] * **RSV疫苗**：Moderna的mRESVIA RSV疫苗预计将在2025年获得批准，并有望在2026年实现显著收入增长。[序号20][序号35] * **CMV疫苗**：Moderna正在开发针对巨细胞病毒（CMV）的疫苗，该疫苗具有巨大的市场潜力，预计每年可带来20亿至50亿美元的收入。[序号36][序号58] 其他重要内容 * **mRNA技术**：Moderna的mRNA技术平台具有组合疫苗的潜力，可以简化疫苗接种并提高疗效。[序号12] * **零售渠道**：在美国，零售渠道在COVID疫苗接种中发挥着重要作用，Moderna计划与零售商合作，以推动其疫苗的销售。[序号16][序号35] * **公共卫生**：Moderna强调其疫苗对公共卫生的重要性，并致力于与政府合作，以应对全球健康挑战。[序号6][序号8] * **教育**：Moderna计划通过教育提高公众对CMV的认识，并确保医生和消费者了解该疫苗的潜在益处。[序号47][序号54]

公司和行业内容 **1. 公司概况** * **公司名称**：Moderna, Inc. (NASDAQ:MRNA) * **公司地位**：全球唯一一家拥有两款在市场上销售mRNA产品的公司 * **主要产品**：COVID疫苗（Spikevax）和RSV疫苗（mRESVIA） **2. 产品和市场** * **COVID疫苗**：预计2024年收入为30亿至35亿美元，市场份额在8亿美元的市场中 * **RSV疫苗**：2024年销售额低于预期，但预计2025年将获得更多市场份额 * **流感疫苗**：预计2025年将获得批准，并有望成为流感季节的常规疫苗 * **其他疫苗**：包括下一代COVID疫苗、流感+COVID组合疫苗、RSV疫苗（18至59岁人群）、CMV疫苗、诺如病毒疫苗等 **3. 研发和管线** * **研发重点**：包括潜伏期和病毒疫苗、癌症和罕见病 * **优先项目**：下一代COVID疫苗、RSV疫苗（18至59岁人群）、流感+COVID组合疫苗、CMV疫苗、诺如病毒疫苗、INT癌症疫苗等 **4. 竞争** * **COVID疫苗**：与辉瑞、阿斯利康等公司竞争 * **RSV疫苗**：与葛兰素史克等公司竞争 * **流感疫苗**：与赛诺菲等公司竞争 **5. 未来展望** * **2025年**：预计将有多款新疫苗获得批准，并有望实现收入增长 * **2026-2028年**：预计将有更多新疫苗上市，并有望实现收入大幅增长 其他重要内容 * **合同**：Moderna与加拿大、英国和澳大利亚政府签订了多年合同，预计将为公司带来稳定的收入 * **优先审查券**：Moderna使用优先审查券加快了RSV疫苗的审批流程 * **市场推广**：Moderna将投资于市场推广活动，以提高其疫苗的知名度和市场份额 * **投资者关系**：Moderna将与投资者保持密切沟通，以分享其进展和未来计划

KEY TAKEAWAYSModerna shares surged further Friday, a day after a senior executive made bullish comments at a healthcare conference about the vaccine maker's pipeline and cash position.Moderna expects to become self-funding by 2028, head of investor relations Lavina Talukdar said at the Jefferies London Healthcare Conference.Moderna stock is down almost 60% this year, however, and—like other vaccine makers—was hit recently by President-elect Donald Trump's nomination of vaccine sceptic Robert F. Kennedy Jr. ...